Annual Reports

 
Quarterly Reports

 
8-K

 
Other

  • 6-K (Mar 12, 2018)
  • 6-K (Mar 9, 2018)
  • 6-K (Mar 5, 2018)
  • SC 13G (Feb 12, 2018)
  • 6-K (Jan 31, 2018)
  • SC 13G (Jan 8, 2018)
Intec Pharma Ltd. 6-K 2016

Documents found in this filing:

  1. 6-K
  2. Ex-99.1
  3. Ex-99.2
  4. Graphic
  5. Graphic

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT of 1934

 

For the month of March 2016

 

001-37521

(Commission File Number)

 

INTEC PHARMA LTD.

(Translation of registrant’s name into English)

 

12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel

(+972) (2) 586-4657

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F  Form 40-F 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________

 

 

 

 

EXPLANATORY NOTE

 

Intec Pharma Ltd. (the “Company”) hereby furnishes the following documents:

 

i.Notice and Proxy Statement with respect to the Company’s special general meeting of the shareholders to be held on April 21, 2016, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting; and

 

ii.a Proxy Card whereby holders of Company’s shares may vote at the meeting without attending in person.

 

The Notice and Proxy Statement is furnished with this Form 6-K as Exhibit 99.1 and the Proxy Card is furnished with this Form 6-K as Exhibit 99.2.

 

 

 

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  INTEC PHARMA LTD.
     
  By: /s/ Zeev Weiss
    Name: Zeev Weiss
    Title: Chief Executive Officer
     
Date: March 25, 2016    

  

 

 

 

EXHIBIT INDEX

 

Exhibit
No.
Description
   
99.1 Notice and Proxy statement for the Special General Meeting of Shareholders of the Company to be held on April 21, 2016.
99.2 Proxy card for the Special General Meeting of Shareholders of the Company to be held on April 21, 2016.

 

 

 

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki